Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease

Jangampalli Adi Pradeepkiran, Arubala P. Reddy, P. Hemachandra Reddy

    Research output: Contribution to journalReview articlepeer-review

    36 Scopus citations


    Phosphorylated tau (P-tau) has received much attention in the field of Alzheimer's disease (AD), as a potential therapeutic target owing to its involvement with synaptic damage and neuronal dysfunction. The continuous failure of amyloid β (Aβ)-targeted therapeutics highlights the urgency to consider alternative therapeutic strategies for AD. The present review describes the latest developments in tau biology and function. It also explains abnormal interactions between P-tau with Aβ and the mitochondrial fission protein Drp1, leading to excessive mitochondrial fragmentation and synaptic damage in AD neurons. This article also addresses 3D pharmacophore-based drug models designed to treat patients with AD and other tauopathies.

    Original languageEnglish (US)
    Pages (from-to)616-623
    Number of pages8
    JournalDrug Discovery Today
    Issue number2
    StatePublished - Feb 2019

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery


    Dive into the research topics of 'Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease'. Together they form a unique fingerprint.

    Cite this